At the news
? BULLISHIMPACT 8/10 8-K filed Apr 9, 2026 at 07:39 ET
ImmunityBio reported preliminary Q1 2026 net product revenue of $44.2 million, a 168% year-over-year increase, driven by continued adoption of ANKTIVA. The company also announced full enrollment in its pivotal BCG-naïve NMIBC trial, with a supplemental BLA submission on track for 2026.
- Preliminary Q1 2026 net product revenue: $44.2 million (168% YoY increase)
- Q1 2026 revenue represents a 15% sequential increase over Q4 2025 ($38.3M)
- Full-year 2025 net product revenue was $113 million, a 700% increase over 2024
- Pivotal BCG-naïve NMIBC CIS trial (QUILT-2.005) is fully enrolled with IDMC confirming adequate statistical power
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access